Earlier suggestions for an overarching National Innovation Partnership to drive innovation through the NHS have been dropped; there are no additional resources, and in the Brexit era, many commentators believe life will get tougher.
Daniel Zeichner MP said: "There are idealistic ideas here, but the mechanisms for actually driving change through the NHS look overly bureaucratic, and there is a real danger that not enough will change. There are also optimistic phrases about new post-Brexit opportunities when the reality is that unless the Government gets a good deal, our pharmaceutical and life sciences industries will suffer. Everyone wants innovative new drugs to reach patients quickly at a price the NHS can afford - but it is not clear that the AAR has really found the way to do that."
________________________________________